相关实验视频
Updated: Sep 9, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
综合查确定GPR31是代谢功能障碍相关的脂肪肝炎的关键驱动因素和可用药物的标
Xiao-Jing Zhang1,2, Jiajun Fu1, Xu Cheng1
1State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
The Journal of clinical investigation
|September 2, 2025
概括
研究人员确定GPR31是代谢功能障碍相关的脂肪肝炎 (MASH) 的关键驱动因素. 在临床前模型中,用新型药物候选物G4451抑制GPR31有效地阻断了MASH的进展,从而提供了一个有前途的新治疗策略.
科学领域:
- 肝病学
- 分子生物学
- 药理学
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种流行性肝病,治疗选择有限.
- 鉴定新型致病基因和治疗点对于MASH治疗至关重要.
研究的目的:
- 进行综合查以确定MASH的基因和标.
- 研究GPR31在MASH病变中的作用.
- 开发和评估针对GPR31的MASH治疗策略.
主要方法:
- 多层查MASH致病基因和可药物标.
- 研究了涉及Gαi3,糖化和PKCδ-MAPK信号的GPR31机制.
- 使用肝细胞特异性GPR31淘汰和转基因小鼠模型.
- 在动物和非人类灵长类动物MASH模型中开发和测试小分子抑制剂G4451.
主要成果:
- 已确定GPR31为MASH的前所未有的关键贡献者.
- 通过Gαi3依赖的PKCδ-MAPK信号的激活,GPR31促进MASH.
- 肝细胞特异性GPR31缺乏改善了MASH,而其过度表达则加重了病情.
- 在临床前模型中,G4451 特别抑制了 GPR31- Gαi3 相互作用并阻断了 MASH 的进展.
结论:
- GPR31是MASH的一个关键治疗点.
- 针对GPR31- Gαi3与G4451的相互作用显示出MASH的显著治疗潜力.
- 干扰GPR31为MASH治疗提供了一个有前途的策略.
相关概念视频
01:15G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79